1. Synthetic approaches towards bedaquiline and its derivatives
- Author
-
Daniel P. Furkert, Christopher B. Cooper, Margaret A. Brimble, and Matthew B. Calvert
- Subjects
Drug ,Azides ,Tuberculosis ,media_common.quotation_subject ,Clinical Biochemistry ,Antitubercular Agents ,Drug Evaluation, Preclinical ,Pharmaceutical Science ,Pharmacology ,Selective inhibition ,01 natural sciences ,Biochemistry ,Catalysis ,Structure-Activity Relationship ,chemistry.chemical_compound ,Diarylquinolines ,Tuberculosis, Multidrug-Resistant ,Drug Discovery ,medicine ,Animals ,Humans ,Molecular Biology ,media_common ,Cycloaddition Reaction ,Molecular Structure ,ATP synthase ,biology ,010405 organic chemistry ,Chemistry ,Organic Chemistry ,Stereoisomerism ,Mycobacterium tuberculosis ,Triazoles ,medicine.disease ,Resistant tuberculosis ,0104 chemical sciences ,010404 medicinal & biomolecular chemistry ,Mechanism of action ,Alkynes ,biology.protein ,Molecular Medicine ,medicine.symptom ,Bedaquiline - Abstract
Bedaquiline is a diarylquinoline drug that demonstrates potent and selective inhibition of mycobacterial ATP synthase, and is clinically administered for the treatment of multi-drug resistant tuberculosis. Due to its excellent activity and novel mechanism of action, bedaquiline has been the focus of a number of synthetic studies. This review will discuss these synthetic approaches, as well as the synthesis and bioactivity of the numerous derivatives and molecular probes inspired by bedaquiline.
- Published
- 2020